Ruth A. Davis

Array ( [id] => 20706568 [patent_doc_number] => 20260130896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-14 [patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES [patent_app_type] => utility [patent_app_number] => 19/441283 [patent_app_country] => US [patent_app_date] => 2026-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19441283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20707820 [patent_doc_number] => 20260132148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-14 [patent_title] => CRYSTAL FORM OF COMPOUND AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/434116 [patent_app_country] => US [patent_app_date] => 2025-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19434116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20445132 [patent_doc_number] => 20260001849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-01 [patent_title] => NOVEL B0AT1 INHIBITOR [patent_app_type] => utility [patent_app_number] => 19/322058 [patent_app_country] => US [patent_app_date] => 2025-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 751 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19322058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20614988 [patent_doc_number] => 20260085074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-26 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 19/241185 [patent_app_country] => US [patent_app_date] => 2025-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19241185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20100216 [patent_doc_number] => 20250230152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-17 [patent_title] => PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS [patent_app_type] => utility [patent_app_number] => 19/097371 [patent_app_country] => US [patent_app_date] => 2025-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26449 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19097371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19862249 [patent_doc_number] => 20250101035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => CRYSTALLINE FORMS OF A MENIN INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/827512 [patent_app_country] => US [patent_app_date] => 2024-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18827512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19940251 [patent_doc_number] => 12312373 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Cyclopropane skeleton monophosphine ligands, palladium complexes thereof, preparation methods and application [patent_app_type] => utility [patent_app_number] => 18/783334 [patent_app_country] => US [patent_app_date] => 2024-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4505 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18783334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743935 [patent_doc_number] => 20250032500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => REVITALIZING EYE DROPS [patent_app_type] => utility [patent_app_number] => 18/782664 [patent_app_country] => US [patent_app_date] => 2024-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4177 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18782664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328363 [patent_doc_number] => 12458620 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Process for production of essentially pure D [patent_app_type] => utility [patent_app_number] => 18/765229 [patent_app_country] => US [patent_app_date] => 2024-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 13587 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18765229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19584932 [patent_doc_number] => 20240382489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => LIQUID PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/667443 [patent_app_country] => US [patent_app_date] => 2024-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18667443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543086 [patent_doc_number] => 20240360122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => POLYMORPHIC FORMS AND SALTS OF A GLP-1R AGONIST [patent_app_type] => utility [patent_app_number] => 18/619638 [patent_app_country] => US [patent_app_date] => 2024-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18619638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403578 [patent_doc_number] => 20240287089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => Preparation and Uses of 7-Azaindenoisoquinolines [patent_app_type] => utility [patent_app_number] => 18/618496 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29245 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462350 [patent_doc_number] => 20240316019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => METHODS OF PREVENTING SYMPTOMATIC ISCHEMIC STROKE [patent_app_type] => utility [patent_app_number] => 18/612570 [patent_app_country] => US [patent_app_date] => 2024-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19785482 [patent_doc_number] => 20250059161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-20 [patent_title] => COMPOUNDS AND METHODS FOR MODULATING STAT3 [patent_app_type] => utility [patent_app_number] => 18/593361 [patent_app_country] => US [patent_app_date] => 2024-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 119444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20452987 [patent_doc_number] => 12516037 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-06 [patent_title] => Substituted thiophenecarboxamides and analogues as antibacterials agents [patent_app_type] => utility [patent_app_number] => 18/591732 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24103 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18591732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389338 [patent_doc_number] => 20240279208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide [patent_app_type] => utility [patent_app_number] => 18/588874 [patent_app_country] => US [patent_app_date] => 2024-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599450 [patent_doc_number] => 20240390330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR REDUCING REDNESS AND INCREASING WHITENESS IN EYES AND OTHER OPHTHALMIC PURPOSES [patent_app_type] => utility [patent_app_number] => 18/434505 [patent_app_country] => US [patent_app_date] => 2024-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18434505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402103 [patent_doc_number] => 20240285614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/433734 [patent_app_country] => US [patent_app_date] => 2024-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18433734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210659 [patent_doc_number] => 11999707 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-06-04 [patent_title] => N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide as an antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/427924 [patent_app_country] => US [patent_app_date] => 2024-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3965 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20451806 [patent_doc_number] => 12514849 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-06 [patent_title] => Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound [patent_app_type] => utility [patent_app_number] => 18/427477 [patent_app_country] => US [patent_app_date] => 2024-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7957 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427477 [rel_patent_id] =>[rel_patent_doc_number] =>)